Research Article
A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer
Figure 5
The tumor-specific targeting of IR783-NBs-Affibody towards HER2 (+)/(−) breast cancer cells. (a, c)The targeting rate of NBs, NBs-Affibody, and IR783-NBs-Affibody for HER2 (+) breast cancer cells (BT-474) and HER2 (−) breast cancer cells (MDA-MB-231) via flow cytometry. (b, d) LSCM pictures of BT-474 and MDA-MB-231 cells coincubated with NBs, NBs-Affibody, and IR783-NBs-Affibody with a ×20 objective lens.
(a) |
(b) |
(c) |
(d) |